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Abstract 
A microwave-assisted, two-step, one-pot synthesis of spiropyrans has been developed. 
This process was used to synthesise a range of sterically-congested spiropyrans from 
readily available precursors, employing environmentally benign solvents. The unusual 
substituent pattern possessed by these structures has been shown to influence the 
stereoselectivity of spiropyran ring-closure.  
 
Introduction 
Spiropyrans (e.g. 2, Scheme 1) are a class of spiro-fused indolochromene that exist in 
photo-controlled equilibrium with their corresponding merocyanine isomer (e.g. 3).1 
The profound structural, electronic and optical differences between these isomers, and 
the controllable nature of this equilibrium, have lead to their widespread use in 
switching and sensing applications.2-5  
Scheme 1 – General synthesis and isomerisation of spiropyrans 
 
Spiropyran synthesis is commonly achieved by condensation of a 2-methylindolium 
salt (e.g. 1) (or the corresponding exo-methylene enamine) with a salicylaldehyde, 
either in refluxing alcohol or ketone solvents with or without an amine base (Scheme 
1).2 Many indolium salts and salicylaldehydes are commercially available and can be 
readily modified; hence, in general, spiropyrans bearing well-defined substituent 
patterns are accessible. It is striking, however, that the vast majority of spiropyrans 
contain gem-dimethyl substituents in their 3-position, and there are few examples that 
possess two different substituents in this position (see Figure 1).6-11 As such, this 
remains an under-explored area of spiropyran research. Given that the 3-position is 
one of only two tetrahedral carbon atoms in the core spiropyran structure – and the 
only one present in the merocyanine form – the incorporation of inequivalent 3-
position substituents impacts upon spiropyran stereochemistry, enabling facial control 
of pyran ring-closure,9,10 and presents an opportunity to influence merocyanine 
complexation of chiral ligands.  
 
 
 Figure 1 – Typical spiropyran 3-position substituents  
 
The synthetic methods that have been employed to control substitution at the 
spiropyran 3-position include defining these substituents in the ketone substrate of 
Fischer indolenine synthesis (Scheme 2a)7 or by use of 3-substituted indoles as π-
nucleophiles in substitution reactions (Scheme 2b), either through direct methylation8-
10
 or by palladium-catalysed allylic substitution.11 Each of these approaches is 
effective in specific cases but lack generality and synthetic convenience; 
consequently, we sought general methodology with which to rapidly transform 
inexpensive and convenient precursors into a range of differentially substituted 
spiropyrans.  
 
Scheme 2 – Syntheses of spiropyrans bearing inequivalent C-3 substituents: (a) via 
Fischer indolenine synthesis; (b) via alkylation.  
 
Recently, De Rosa has shown that indoles lacking C-2 or C-3 substituents undergo 3-
selective Friedel–Crafts alkylation in a notable catalyst-free, microwave-promoted 
SN1 process conducted in water (Scheme 3a).12 We envisaged that this methodology 
could be extended to encompass indolium salt synthesis, i.e. that 2-methyl-3-alkyl 
indoles (e.g. 4) would behave as viable substrates for this 3-selective alkylation to 
give 3,3-disubstituted indolium salts (5), which in turn would give access to 
spiropyrans (6) via condensation with salicylaldehydes (Scheme 3b). Such indolium 
salt/salicylaldehyde condensations can be accelerated by microwave irradiation;13 
consequently, we surmised that our approach to differentially substituted spiropyrans 
might be achieved as a two-step, one-pot procedure, utilising microwave irradiation in 
each step. This methodology is potentially efficient and convenient: microwave-
promoted reactions are typically rapid and energy efficient;14 environmentally benign 
solvents are employed; and both indole and electrophile substrates are readily 
accessible. The research presented herein describes the development and optimisation 
of this process, and exploration of its scope and limitations through application to a 
range of substrates. 
 
  
Scheme 3 – Microwave assisted indole alkylation: (a) Prior research by De Rosa and 
Soriente; (b) As applied to spiropyran synthesis, explored in this research.   
 
Results and Discussion 
Our initial studies sought to establish the viability of the proposed synthetic strategy. 
Treatment of 1,2,3-trimethylindole (4a) with benzyl bromide (2 eq.) in water, using 
De Rosa and Soriente’s conditions (microwave heating, sealed tube, 200 W, 150 °C, 8 
minutes), gave crude indolium salt 5a. The instability of indolium salts is well-
documented;15 consequently, 5a was reacted directly with 5-nitrosalicylaldehyde (7) 
(1.2 eq.) in refluxing ethanol for 18 hours. Gratifyingly, this produced 3-benzyl-3-
methylspiropyran 6a in 65% yield over 2 steps (Table 1; entry 1). For comparison, the 
corresponding alkylation process employing standard thermal conditions (open reflux 
apparatus, 100 °C) failed to reach 25% conversion after 24 hours (entry 2). With this 
positive result in hand, we successfully repeated this 2-step process, this time using 
microwave irradiation for both steps (sealed tube, 200 W, 150 °C, 8 minutes for both 
steps; alkylation in water, condensation in ethanol) and this enabled us to synthesise 
6a with a total heating time under 20 minutes and in 77% yield (entry 3). We then 
performed further studies to optimise the balance between stoichiometry, heating 
duration and yield, initially focussing upon the alkylation step. An increased heating 
period had little impact upon yield in the presence of 2 eq. benzyl bromide (compare 
entries 3 and 4); however, if fewer molar equivalents were used, increased heating 
duration became relevant (compare entries 5 and 6) and it was possible to maintain 
the yield of 6a using 1.5 eq. benzyl bromide allied to a longer reaction time (compare 
entries 3 and 6). As such, conditions could be chosen to meet the priorities of a given 
reaction, either in terms of energy efficiency or atom economy. These results were 
achieved by employing two consecutive 8 minute heating periods with the 
temperature held at 150 °C, separated by intermediate cooling to 60 °C. An alternative 
protocol, employing a hold time at 150 °C for 16 minutes, was less effective (entry 7) 
and we speculate that this reflects the reduced microwave energy input in this latter 
case. Alkylation yield decreased dramatically if 1 equivalent of benzyl bromide was 
used (entry 8), regardless of heating protocol. With respect to the second step, 
spiropyran yield was unaffected by increased salicylaldehyde concentration (entry 9) 
whilst relative amounts lower than 1.2 eq. proved unsatisfactory (entry 10). Attempts 
to perform both steps in the same solvent, to obviate the requirement of swapping 
water for ethanol, were ineffective (entries 11 and 12), as was a tandem (as opposed 
to telescoped) process. 
Overall, we regard conditions that minimise reagent waste without compromising 
yield as optimal (i.e. those represented by entry 6) and in this way, we were able to 
access 6a in excellent yield (77% overall, 88% per step) and operational simplicity. 
 
 
Table 1 – Optimisation of two-step, one-pot microwave-assisted spiropyran synthesis 
 
 
Alkylation Condensation Entry 
BnBr 
 / Eq. 





1 2 Method A 1.2 Method E 65 
2 2 Method B - - - 
3 2 Method A 1.2 Method F 77 
4 2 Method C 1.2 Method F 78 
5 1.5 Method A 1.2 Method F 66 
6 1.5 Method C 1.2 Method F 77 
7 1.5 Method D 1.2 Method F 69 
8 1 Method C 1.2 Method F 45 
9 1.5 Method C 1.5 Method F 77 
10 1.5 Method C 1 Method F 70 
11 2 Method A 1.2 Method A - 
12 2 Method F 1.2 Method F - 
a: All reaction stoichiometry based upon 4a (0.622 mmol, 1 eq.); maximum 
microwave power = 200 W: Method A – microwave irradiation, sealed tube, 8 
minutes at 150 °C, water (1 mL); Method B – oil bath, open reflux apparatus, 24 h at 
100 °C, water (1 mL); Method C – microwave irradiation, sealed tube, 2 × 8 mins at 
150 °C, water (1 mL); Method D – microwave irradiation, sealed tube, 16 mins at 150 
°C, water (1 mL); Method E – oil bath, open reflux apparatus, 18 h at 78 °C, ethanol 
(3 mL); Method F – microwave irradiation, sealed tube, 8 mins at 150 °C, ethanol (3 
mL). b: Isolated yield. 
 
With optimised conditions in hand, we explored the scope of this reaction sequence 
with respect to alternative substituent patterns (Table 2). In general, classical SN 
electrophiles were well tolerated (e.g. benzylic-, allylic- and propargylic bromides; 
entries 1 – 7), although tbutyl bromide was not a viable substrate for this reaction 
(entry 12). Given that this process involves quaternisation of C-3 and formation of 
spiropyran structures with a pair of contiguous quaternary carbon atoms, we assume 
that incorporation of a tbutyl group is unfeasible in this sterically demanding 
environment. Several SN2 electrophiles were viable substrates: a modest yield of 
spiropyran 6i was produced via reaction with iodomethane (entry 9); whilst a good 
yield of 6h was produced using an α-bromocarbonyl reagent (entry 8). Less reactive 
primary and secondary alkyl halides were ineffective substrates under these 
conditions (entries 10 and 11). Reaction of benzylic electrophiles remained effective 
with more hindered indole nucleophile 4b (entries 13 and 14, R1 = Et) and the 
consequent formation of sterically congested 6n, in particular, provides a pleasing 
result. Alternative substituents were tolerated both on the indole nitrogen (6o; entry 
15: a removable protecting group) and on the chromene ring (6p and 6q; entries 16 
and 17).  
As with many nucleophilic substitutions, the balance between SN1 and SN2 pathways 
in this alkylation process is not clear-cut.16 The inefficient nature of the reaction with 
methyl and n-hexyl halides would suggest that SN1 is the predominant mechanism (as 
previously stated, we assume that t-butyl bromide was unreactive on steric grounds). 
Although water – as a polar, protic solvent – favours nucleophilic substitution via SN1 
over SN2, when heated to near-critical temperature (150 – 300 °C) the polarity of 
water drops considerably (25 °C: ε = 78.5; 250 °C: ε = 27.1; cf. acetonitrile: ε = 
36.6)17 and, in this state, it can be regarded as a pseudo-organic solvent suitable for 
SN2 reactions.18,19 Given that we are operating at the lower end of the near-critical 
temperature range, this, perhaps, explains the grudging tolerance of this reaction for 
more reactive SN2 substrates whilst providing greater acceleration for reactions of 
substrates capable of SN1.  
 
 
Table 2 – Application of optimised methodology in spiropyran synthesis over a range 
of indole, alkyl bromide and salicylaldehyde substrates  
 
 
Entrya R1 R2 R3 R4 Product Yieldb Syn:antic 
1 Me Bn Me NO2 6a 77% 25 : 75 
2 Me 2-NO2C6H4CH2 Me NO2 6b 80% 15 : 85 
3 Me 4-NO2C6H4CH2 Me NO2 6c 86% 22 : 78 
4 Me 2-BrC6H4CH2 Me NO2 6d 75% 14 : 86 
5 Me 4-BrC6H4CH2 Me NO2 6e 83% 23 : 77 
6 Me Allyl Me NO2 6f 73% 44 : 56 
7 Me Propargyl Me NO2 6g 80% 48 : 52 
8 Me PhCOCH2 Me NO2 6h 77% 67 : 33 
9 Me Med Me NO2 6i 30% - 
10 Me n-hexyl Me NO2 6j - - 
11 Me i-Pr Me NO2 6k - - 
12 Me t-butyl Me NO2 6l - - 
13 Et Bn Me NO2 6m 76% 33 : 67 
14 Et 2-BrC6H4CH2 Me NO2 6n 66% 17 : 83 
15 Me Bn Bn NO2 6o 74% 22 : 78 
16 Me Bn Me Br 6p 83% 27 : 73 
17 Me Bn Me CO2Me 6q 70% 26 : 74 
a. General conditions: Alkylation – 4 (1 eq.), R2Br (1.5 eq.), water (1 mL/0.6 mmol 4); 
microwave irradiation (maximum power = 200 W), sealed tube, 2 × 8 mins at 150 °C. 
Condensation – salicylaldehyde (1.2 eq.), ethanol (3 mL/0.6 mmol 4); microwave 
irradiation (maximum power = 200 W), sealed tube, 8 mins at 150 °C. b. Isolated 
yield. c. Determined by NOESY analysis. d. Iodomethane used. 
 
With the exclusion of 6i, each spiropyran product exists in solution as a dynamic 
diastereomeric mixture, reflecting the equilibrium between spiro and mero forms and 
the facial selectivity of phenoxide attack upon the merocyanine iminium ion during 
ring closure. Facial selectivity is influenced by the stereoelectronic environment 
imposed by the adjacent chiral centre (C-3) and this is reflected in the diastereomeric 
ratios observed in 6a-h and 6m-q (Table 2). Assignment of syn- and anti-
configurations was achieved through identification of through-space interactions 
between alkene protons (chromene 3-position) and either protons on R1 or R2 (indole 
3-position) by NOESY analysis (Figure 2). Diastereomeric ratios could then be 
estimated on the basis of 1H NMR integral values. In general, a preference is shown 
for structures that minimise steric interaction between the larger group on C-3 and the 
chromene oxygen atom (i.e. anti-6a), and this is consistent with prior studies.9,10 
Ketone 6h, however, provides an exception to this pattern, in which the major syn-
isomer minimises interaction between carbonyl and alkene. Higher drs result from 
structures possessing the greatest difference in size between C-3 substituents and C-3 
benzylic groups bearing an ortho substituent showed the greatest influence upon 
diastereoselection (e.g. 6b and 6d). 
 
Figure 2 – Determination of spiropyran relative stereochemistry by NOESY analysis  
 
Conclusion 
In summary, we have developed a convenient two-step, one-pot protocol which 
enables rapid access to spiropyran structures displaying a largely neglected pattern of 
substitution, from readily available precursors, in environmentally benign solvents. Of 
crucial importance is that this methodology can be used to incorporate a range of 
functional groups into the spiropyran nucleus that provide convenient handles for 
further functionalisation, e.g. through Pd(0) cross coupling (6e), metathesis (6f), click 
chemistry (6g) or carbonyl chemistry (6h). We intend to explore fully the scope of 
this new methodology with respect to substrate tolerance and diastereomeric bias in 





Solvents and reagents were used as commercially supplied. The fraction of light 
petroleum ether boiling in the range 40 to 60 °C is referred to as “petrol”. Water refers 
to deionised water. Analytical thin layer chromatography was carried out using Merck 
Kieselgel 60 F254, coated on aluminium plates, with visualisation of spots where 
necessary by quenching of UV(254 nm) fluorescence. Silica gel with particle size 40–
63 mm was used for flash chromatography. 
Microwave reactions were performed in a CEM Discover microwave in 10 mL, thick-
walled microwave tubes, sealed with septum caps. All microwave reactions were 
magnetically stirred and conducted with simultaneous compressed air cooling to 
maximise microwave radiation input.  
Infrared spectra were recorded as thin films using attenuated total reflectance with a 
Nicolet iS5 FTIR spectrometer. Mass spectra were recorded on a QToF 6520 mass 
spectrometer (Agilent Technologies, Palo Alto, USA). 1H NMR and 13C NMR spectra 
were recorded at 400 MHz and 100 MHz respectively, using a Bruker Avance III 
HD400 spectrometer. Chemical shifts are quoted in ppm relative to tetramethylsilane, 
the residual solvent peak being used for referencing purposes. Coupling constants are 
quoted to the nearest 0.1 Hz with peak multiplicities for single resonances being 
labelled as: s, singlet; d, doublet; t, triplet; q, quartet; m, unresolved multiplet. NMR 
assignments of spiropyrans and merocyanines are labelled as depicted in Figure 3, 
using 6a as an example. 
 
 Figure 3 – Atom labelling in 6a for NMR assignment: (left) spiropyran; (right) 
merocyanine 
 
The majority of compounds documented in this publication exist in solution as 
equilibrating mixtures of spiropyran diastereoisomers which interconvert via their 
merocyanine form. The merocyanines themselves can exist as zwitterionic (denoted 
“MC”), protonated (“MCH”) or quinoidal (“MCQ”) forms. Although interpretation of 
NMR spectra from such multicomponent mixtures is challenging due to overlapping 
resonances and broadened signals from charged species, and full analysis is often 
impossible, we have sought to assign nuclei as far as we can within reasonable doubt 
and merocyanine:syn:anti ratios are quoted for each 1H NMR spectrum. All spectra 
were obtained in deuterochloroform which favours the spiropyran form; hence we 
have assigned all resonances from both spiropyran diastereoisomers. Resonances 
attributable to merocyanine nuclei have only been noted where not overlapped. 2D 
NOESY experiments were used – and proved invaluable – for assignment of 1H NMR 
spectra and for determination of relative configurations. 
 
Synthesis of indole precursors 
1,2,3-Trimethylindole20 4a 
Anhydrous DMF (20 mL) was added slowly to sodium hydride (661 mg of a 60% 
dispersion in mineral oil, 16.5 mmol) under N2 with stirring. To the resulting 
suspension were added slowly 2,3-dimethylindole (2 g, 13.8 mmol) then iodomethane 
(946 µL, 15.2 mmol). After stirring under N2 for 22 h, the reaction was quenched with 
water (20 mL) and extracted with toluene (3 × 20 mL). The combined organic extracts 
were dried (MgSO4) and concentrated under reduced pressure. The resulting crude 
product was purified by flash chromatography, eluting with 2:98 then 5:95 ethyl 
acetate:petrol, to give 1,2,3-trimethylindole 4a (2.032 g, 92%) as a pale yellow oil, 
spectroscopically identical to that previously reported.20 
 
1-Benzyl-2,3-dimethylindole21 4b  
Using the same general method, 2,3-dimethylindole (200 mg, 1.38 mmol), sodium 
hydride (66 mg of a 60% dispersion in mineral oil, 1.65 mmol) and benzyl bromide 
(181 µL, 1.52 mmol) in DMF (3 mL) gave 1-benzyl-2,3-dimethylindole 4b (230 mg, 
71%) as a pale yellow oil, spectroscopically identical to that previously reported.21 
 
3-Ethyl-1,2-dimethylindole22 4c 
A stirred solution of 1-methyl-1-phenylhydrazine (481 µl, 4.09 mmol) and 2-
pentanone (871 µL, 8.18 mmol) in glacial acetic acid (4 mL) was heated to 100 °C for 
22 hours. The reaction was cooled to room temperature then concentrated under 
reduced pressure. The resulting crude product was purified by flash chromatography, 
eluting with 2:98 then 3:97 ethyl acetate:petrol, to give 3-ethyl-1,2-dimethylindole 4c 
(481 mg, 68%) as a pale yellow oil, spectroscopically identical to that previously 
reported.22 
 
Synthesis of Spiropyrans 
Example procedure for microwave-assisted spiropyran synthesis 
Anti-(2R*,3S*)- and syn-(2R*,3R*)-3-benzyl-1,3-dimethyl-6′-
nitrospiro[chromene-2,2'-indoline] 6a 
A microwave reactor tube equipped with a magnetic follower was charged with a 
mixture of 1,2,3-trimethylindole (99 mg, 0.622 mmol), benzyl bromide (111 µL, 
0.933 mmol) and water (1 mL) and sealed with a septum cap. The reaction mixture 
was stirred and heated to 150 °C under microwave irradiation (maximum power = 200 
W), held at 150 °C for 8 minutes, allowed to cool to 60 °C, then reheated to 150 °C 
and held at 150 °C for 8 minutes. After cooling to room temperature, the resulting red 
solution was concentrated under reduced pressure and dissolved in ethanol (3 mL). To 
this solution was added 5-nitrosalicylaldehyde (125 mg, 0.746 mmol) and the 
microwave tube was sealed with a septum cap. The reaction mixture was stirred and 
heated to 150 °C under microwave irradiation (maximum power = 200 W) and held at 
150 °C for 8 minutes, then cooled to room temperature and concentrated in vacuo. 
The resulting crude product was purified by flash chromatography, eluting with ethyl 
acetate, then 10% methanol in ethyl acetate, then 50% methanol in ethyl acetate. The 
product thus produced was dissolved in dichloromethane and filtered through paper 
(to remove silica) to give the spiropyran 6a (191 mg, 77%) as an amorphous purple 
film, Rf 0.3 (5:95 methanol:ethyl acetate); νmax = 3028, 2927, 1709, 1609, 1517, 1481, 
1335, 1272, 1220, 1088, 951, 920, 806 and 747 cm–1; δH(400 MHz; CDCl3; 5:24:71 
MC:syn:anti) 8.50 - 8.20 (2 H, m, MC 5'-, 7'-H), 8.01 (1 H, dd, J 9.0, 2.7, 7'-H syn), 
7.98 - 7.93 (2 H, m, 5'-H anti; 5'-H syn), 7.91 (1 H, dd, J 8.7, 2.7, 7'-H anti), 7.48 - 
7.42 (5 H, m, MC), 7.19 - 6.98 (11 H, m, 6-, b-, c-H anti; 4-, 6-, b-, c-H syn), 6.94 - 
6.92 (2 H, m, a-H syn), 6.92 (1 H, d, J 10.4, 4'-H anti), 6.85 (1 H, d, J 9.0, 8'-H syn), 
6.80 (1 H, t, J 7.5, 5-H syn), 6.69 (1 H, d, J 8.7, 8'-H anti), 6.64 - 6.56 (4 H, m, 5-, a-
H anti; 4'-H syn), 6.55 (1 H, d, J 7.5, 7-H anti), 6.48 (1 H, d, J 7.5, 7-H syn), 6.10 (1 
H, d, J 7.5, 4-H anti), 5.96 (1 H, d, J 10.4, 3'-H anti), 5.57 (1 H, d, J 10.3, 3'-H syn), 
3.82 - 3.70 (4 H, m, MC NMe, CHH), 3.50 (1 H, br s, MC CHH), 3.17 (1 H, d, J 
13.6,CHH syn), 3.08 (1 H, d, J 13.6,CHH syn), 2.73 (3 H, s, NMe anti), 2.72 (1 H, d, 
J 12.2, CHH anti), 2.62 (1 H, d, J 12.2, CHH anti), 2.52 (3 H, s, NMe syn), 1.30 (3 H, 
s, MC CMe ), 1.20 (3 H, s, CMe syn) and 1.18 (3 H, s, CMe anti); δC(100 MHz; 
CDCl3); anti diastereoisomer: 160.0, 148.2, 141.0, 136.7, 131.6, 130.9, 128.8, 128.0, 
127.6, 127.3, 126.4, 126.0, 125.0, 122.8, 121.8, 118.6, 115.6, 107.7, 107.1 (2-C), 57.3 
(3-C), 41.5 (CH2), 29.3 (NMe) and 16.6 (3-Me); syn diastereoisomer: 159.1, 147.0, 
141.1, 137.4, 135.7, 132.0, 127.0, 126.4, 125.8, 122.8, 122.7, 122.3, 120.9, 119.8, 
119.2, 118.8, 115.7, 107.3, 104.6 (2-C), 54.4 (3-C), 39.3 (CH2), 28.1 (NMe) and 23.8 




Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), 2-
nitrobenzyl bromide (202 mg, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 
0.746 mmol) gave spiropyran 6b (221 mg, 80%) as a purple amorphous film, Rf 0.1 
(5:95 methanol:ethyl acetate); νmax = 2970, 1708, 1606, 1520, 1334, 1269, 1087, 950, 
807 and 747 cm–1; δH(400 MHz; CDCl3; 8:14:78 MC:syn:anti) 8.40 (1 H, br s, MC 
5'-H), 8.10 (1 H, br d, J 15.3, MC 4'-H), 8.03 (1 H, dd, J9.0, 2.7, 7'-H syn), 7.96 (1 H, 
d, J 2.7, 5'-H syn), 7.96 (1 H, d, J 2.7, 5'-H anti), 7.92 (1 H, dd, J 8.9, 2.7, 7'-H anti), 
7.70 (1 H, dd, J 7.0, 1.9, a-H anti), 7.67 (1 H, d, J 8.0, a-H syn), 7.52 - 7.44 (4 H, m, 
MC), 7.37 - 7.28 (3 H, m, b-, c-H anti; b-H syn), 7.24 (1 H, t, J 8.0, c-H syn), 7.16 (1 
H, dt, J 7.5, 1.0, 6-H anti), 7.16 - 7.14 (1 H, m, 6-H syn), 6.97 (1 H, d, J 10.4, 4'-H 
anti), 7.12 (1 H, d, J 7.5, 4-H syn), 6.89 (1 H, d, J 9.0, 8'-H syn), 6.78 (1 H, t, J 7.5, 5-
H syn), 6.75 - 6.70 (2 H, m, d-H anti; 4'-H syn), 6.67 (1 H, d, J 8.9, 8'-H anti), 6.67 (1 
H, m, d-H syn), 6.57 (1 H, t, J 7.5, 5-H anti), 6.56 (1 H, d, J 7.5, 7-H anti), 6.41 (1 H, 
d, J 7.5, 7-H syn), 5.99 (1 H, d, J 10.4, 3'-H anti), 5.95 (1 H, d, J 7.5, 4-H anti), 5.58 
(1 H, d, J 10.3, 3'-H syn), 4.08 (3 H, br s, MC NMe), 3.90 (1 H, d, J 14.2, CHH syn), 
3.77 (1 H, br d, J 13.0, MC CHH), 3.42 (1 H, d, J 14.2, CHH syn), 3.31 (1 H, d, J 
12.5, CHH anti), 3.21 (1 H, d, J 12.5, CHH anti), 2.72 (3 H, s, NMe anti), 2.50 (3 H, 
s, NMe syn), 1.18 (3 H, s, CMe syn), 1.14 (3 H, s, MC CMe) and 1.03 (3 H, s, CMe 
anti); δC(100 MHz; CDCl3); anti diastereoisomer: 159.7, 151.0, 148.4, 141.1, 134.9, 
131.8, 131.5, 131.1, 129.3, 128.6, 127.8, 126.0, 124.5, 123.8, 122.8, 121.3, 119.1, 
118.8, 115.6, 107.5, 107.4 (2-C), 57.6 (3-C), 36.0 (CH2), 29.3 (NMe) and 16.3 (3-
Me); syn diastereoisomer: 158.7, 151.2, 146.6, 141.5, 134.3, 134.0, 132.3, 131.6, 
128.4, 127.6, 127.2, 125.9, 124.6, 122.7, 122.3, 120.8, 119.9, 119.2, 115.9, 107.4, 
104.4 (2-C), 55.0 (3-C), 33.8 (CH2), 28.2 (NMe) and 22.2 (3-Me); HRMS-ES (m/z): 




Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), 4-
nitrobenzyl bromide (202 mg, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 
0.746 mmol) gave spiropyran 6c (237 mg, 86%) as a purple amorphous film, Rf 0.2 
(5:95 methanol:ethyl acetate) νmax = 2929, 1708, 1604, 1515, 1480, 1335, 1269, 1220, 
1176, 1086, 949, 806 and 747 cm–1; δH(400 MHz; CDCl3; 5:21:74 MC:syn:anti) 8.60 
(1 H, br d, J 16.1, MC 4'-H), 8.56 (1 H, br s, MC 5'-H), 8.50 (1 H, d, J 2.7, MCQ 5'-
H), 8.33 (1 H, dd, J 9.0, 2.7, MCQ 7'-H), 8.03 (1 H, dd, J 9.0, 2.7, 7'-H syn), 7.98 - 
7.92 (4 H, m, 5'-, 7'-, b-H anti; 5'-H syn), 7.88 (2 H, d, J 8.7, b-H syn), 7.82 (2 H, br d, 
J 8.5, MC b-H), 7.60 - 7.52 (4 H, m, MC), 7.38 (1 H, br d, J 7.9, MC), 7.33 (1 H, br d, 
J 8.6, MC), 7.19 (1 H, t, J 7.5, 6-H syn), 7.18 (1 H, t, J 7.5, 6-H anti), 7.10 (2 H, d, J 
8.7, a-H syn), 6.96 (1 H, d, J 10.4, 4-H anti), 6.95 (1 H, d, J 7.5, 4-H syn), 6.87 (1 H, 
d, J 9.0, 8'-H syn), 6.81 (1 H, t, J 7.5,5-H syn), 6.75 (2 H, d, J 8.7, a-H anti), 6.69 (1 
H, d, J 8.7, 8'-H anti), 6.65 (1 H, d, J 10.3, 4'-H syn), 6.62 (1 H, t, J 7.5, 5-H anti), 
6.53 (1 H, d, J 7.5, 7-H anti), 6.48 (1 H, d, J 7.5, 7-H syn), 6.09 (1 H, d, J 7.5, 4-H 
anti), 5.93 (1 H, d, J 10.43'-H anti), 5.57 (1 H, d, J 10.3, 3'-H syn), 3.72 (2 H, br s, 
MC CH2), 3.30 (1 H, d, J 13.5, CHH syn), 3.18 (1 H, d, J 13.5, CHH syn), 2.83 (1 H, 
d, J 12.0, CHH anti), 2.76 (1 H, d, J 12.0, CHH anti), 2.73 (3 H, s, NMe anti), 2.58 (3 
H, s, NMe syn), 1.22 (3 H, s, CMe syn), 1.18 (3 H, s, MC CMe) and 1.15 (3 H, s, 
CMe anti); δC(100 MHz; CDCl3); anti diastereoisomer: 159.7, 148.3, 146.8, 144.9, 
141.2, 132.2, 129.4, 128.6, 126.1, 124.5, 122.8, 122.7, 122.5, 121.1, 118.9, 118.7, 
115.7, 107.6, 107.3 (2-C), 57.1 (3-C), 41.4 (CH2), 29.3 (NMe) and 16.5 (3-Me); syn 
diastereoisomer: 158.6, 146.7, 145.6, 141.5, 134.5, 131.6, 131.1, 128.5, 127.3, 126.0, 
122.7, 122.5, 120.6, 119.9, 119.1, 115.7, 107.5, 104.2 (2-C), 54.2 (3-C), 39.4 (CH2), 
28.1 (NMe) and 23.5 (3-Me) (one peak missing); HRMS-ES (m/z): Found: 444.1562 




Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), 2-
bromobenzyl bromide (233 mg, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 
0.746 mmol) gave spiropyran 6d (223 mg, 75%) as a purple amorphous film, Rf 0.2 
(5:95 methanol:ethyl acetate); νmax = 2930, 1710, 1608, 1519, 1471, 1337, 1273, 
1088, 951, 807 and 749 cm–1; δH(400 MHz; CDCl3; 5:17:11:67 MCQ:MC:syn:anti) 
8.49 (1 H, d, J 2.7, MCQ 5'-H), 8.33 (1 H, dd, J 9.2, 2.7, MCQ 7'-H), 8.25 (1 H, d, J 
2.6, MC 5'-H), 8.05 (1 H, d, J 16.3, MC 4'-H), 8.00 - 7.91 (4 H, m, 5'-, 7'-H anti; 5'-, 
7'-H syn), 7.84 (1 H, d, J 16.3, MC 3'-H), 7.75 (1 H, d, J 9.2, MC), 7.55 - 7.42 (5 H, 
m, MC), 7.39 (1 H, dd, J 7.8, 1.4, a-H anti), 7.30 (1 H, d, J 8.0, a-H syn), 7.16 (1 H, 
dd, J 7.5, 1.1, 6-H anti), 7.16 - 7.14 (1 H, m, 6-H syn), 7.07 - 6.97 (4 H, m, b-, c-H 
anti; b-, c-H syn), 6.96 (1 H, d, J 10.4, 4'-H anti), 6.83 (1 H, d, J 7.5, 8'-H syn), 6.82 - 
6.76 (2 H, m, 4'-, 5-H syn), 6.69 (1 H, d, J 8.9, 8'-H anti), 6.69 - 6.67 (1 H, m, 4-H 
syn), 6.62 (1 H, dd, J 7.5, 0.7, 5-H anti), 6.57 (1 H, dd, J 7.5, 1.8, d-H anti), 6.57 - 
6.54 (1 H, m, d-H syn), 6.52 (1 H, d, J 7.5, 7-H anti), 6.47 (1 H, d, J 7.5, 7-H syn), 
6.13 (1 H, d, J 7.5, 4-H anti), 5.99 (1 H, d, J 10.4, 3'-H anti), 4.10 (3 H, s, MC NMe), 
3.58 (1 H, d, J 14.2, CHH syn), 3.55 (1 H, d, J 14.0, MC CHH), 3.43 (1 H, d, J 14.0, 
MC CHH), 3.26 (1 H, d, J 14.2, CHH syn), 2.99 (1 H, d, J 12.4, CHH anti), 2.86 (1 H, 
d, J 12.4, CHH anti), 2.76 (3 H, s, NMe anti), 2.58 (3 H, s, NMe syn), 1.21 (3 H, s, 
CMe syn), 1.20 (3 H, s, MC CMe) and 1.18 (3 H, s, CMe anti); δC(100 MHz; 
CDCl3); anti diastereoisomer: 160.0, 148.7, 141.0, 136.5, 133.6, 132.7, 131.9, 129.0, 
128.3, 128.2, 127.2, 126.2, 126.0, 124.6, 122.8, 121.7, 119.0, 118.8, 115.6, 107.6, 
107.3 (2-C), 57.8 (3-C), 39.4 (CH2), 29.3 (NMe) and 16.9 (3-Me); syn 
diastereoisomer: 159.0, 146.8, 141.4, 137.5, 134.9, 133.0, 132.8, 132.5, 128.9, 128.0, 
127.3, 126.9, 126.7, 126.1, 125.9, 121.5, 119.7, 119.2, 116.0, 107.2, 104.8 (2-C), 55.0 
(3-C), 37.5 (CH2), 28.3 (NMe) and 22.8 (3-Me); HRMS-ES (m/z): Found: 477.0809 




Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), 4-
bromobenzyl bromide (233 mg, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 
0.746 mmol) gave spiropyran 6e (246 mg, 83%) as a purple amorphous film, Rf 0.2 
(5:95 methanol:ethyl acetate); νmax = 2926, 1709, 1610, 1517, 1481, 1333, 1270, 
1071, 949, 804 and 746 cm–1; δH(400 MHz; CDCl3; 7:22:71 MC:syn:anti) 8.51 (1 H, 
br d, J 2.1, MC 5'-H), 8.45 (1 H, br d, J 16.2, MC 4'-H), 8.02 (1 H, dd, J 9.0, 2.7, 7'-H 
syn), 7.97 - 7.91 (3 H, m, 5'-, 7'-H anti; 5'-H syn), 7.82 (1 H, br d, J 16.2, MC 3'-H), 
7.78 (1 H, br d, J 9.3, MC), 7.54 - 7.48 (2 H, m, MC), 7.40 - 7.34 (2 H, m, MC), 7.22 
(2 H, d, J 8.3, b-H anti), 7.20 - 7.12 (4 H, m, 6-H anti; 6-, b-H syn), 7.08 (2 H, d, J 
8.3, MC a-H), 6.98 (1 H, d, J 7.5, 4-H syn), 6.93 (1 H, d, J 10.4, 4'-H anti), 6.86 - 6.78 
(4 H, m, a-, 8'-, 5-syn), 6.68 (1 H, d, J 8.4, 8'-H anti), 6.64 (1 H, d, J 10.3, 4'-H syn), 
6.62 (1 H, t, J 7.5, 5-H anti), 6.54 (1 H, d, J 7.5, 7-H anti), 6.42 (1 H, d, J 7.5, 7-H 
syn), 6.14 (1 H, d, J 7.5, 4-H anti), 5.92 (1 H, d, J 10.4, 3'-H anti), 5.57 (1 H, d, J 
10.3, 3'-H syn), 3.92 (3 H, br s, MC NMe), 3.50 (2 H, br s, MC CHH), 3.14 (1 H, d, J 
13.6, CHH syn), 3.04 (1 H, d, J 13.6, CHH syn), 2.73 (3 H, s, NMe anti), 2.66 (1 H, d, 
J 12.2, CHH anti), 2.58 (1 H, d, J 12.2, CHH anti), 2.52 (3 H, s, NMe syn), 1.19 (3 H, 
s, CMe anti) and 1.11 (3 H, s, CMe syn); δC(100 MHz; CDCl3); anti diastereoisomer: 
159.9, 148.2, 141.0, 135.8, 133.2, 132.5, 130.7, 130.4, 129.0, 128.2, 126.1, 124.9, 
122.8, 121.6, 120.6, 118.7, 115.6, 107.5, 107.3 (2-C), 57.1 (3-C), 40.9 (CH2), 29.3 
(NMe) and 16.5 (3-Me); syn diastereoisomer: 158.9, 146.9, 141.3, 136.4, 135.2, 
131.6, 131.5, 128.2, 127.2, 125.9, 122.7, 122.2, 120.8, 120.5, 119.8, 119.2, 115.7, 
107.4, 104.4 (2-C), 54.1 (3-C), 38.7 (CH2), 28.1 (NMe) and 23.6 (3-Me); HRMS-ES 




Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), allyl 
bromide (81 µL, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 0.746 mmol) gave 
spiropyran 6f (159 mg, 73%) as a purple amorphous film, Rf 0.3 (5:95 methanol:ethyl 
acetate); νmax = 2973, 1707, 1582, 1518, 1485, 1335, 1281, 1087, 948, 834 and 748 
cm–1; δH(400 MHz; CDCl3; 3:5:43:49 MCQ:MC:syn:anti) 8.39 (1 H, br s, MC 5'-H), 
8.31 (1 H, br d, J 15.0, MC 4'-H), 8.15 (1 H, d, J 2.7, MCQ 5'-H), 8.07 (1 H, dd, J 7.5, 
2.7, MCQ 7'-H), 7.96 (1 H, dd, J 8.9, 2.7, 7'-H anti), 7.95 - 7.90 (3 H, m, 5'-H anti; 5'-
, 7'-H syn), 7.90 - 7.80 (4 H, m, MC / MCQ), 7.74 (1 H, dd, J 8.9, 2.7, MC 7'-H), 7.55 
- 7.40 (6 H, m, MC / MCQ), 7.36 - 7.30 (1 H, m, MC), 7.15 (1 H, dt, J 7.5, 1.2, 6-H 
anti), 7.13 (1 H, dt, J 7.5, 1.2, 6-H syn), 7.07 (1 H, dd, J 7.5, 0.7, 4-H syn), 7.04 - 6.96 
(4 H, m, MC / MCQ), 6.94 (1 H, dd, J 7.5, 0.8, 4-H anti), 6.85 (1 H, d, J 10.4, 4'-H 
anti), 6.82 (1 H, dt, J 7.5, 0.9, 5-H syn), 6.81 (1 H, d, J 10.3, 4'-H syn), 6.74 (1 H, br 
d, J 7.0, MC), 6.72 (1 H, d, J 8.8, 8'-H anti), 6.68 (1 H, d, J 8.4, 8'-H syn), 6.64 - 6.53 
(3 H, m, MC / MCQ), 6.51 (1 H, d, J 7.5, 7-H anti), 6.47 (1 H, d, J 7.5, 7-H syn), 6.32 
(1 H, d, J 16.4, MC b-H), 6.23 (1 H, d, J 16.3, MCQ b-H), 5.84 (1 H, d, J 10.4, 3'-H 
anti), 5.79 (1 H, d, J 10.3, 3'-H syn), 5.68 (1 H, ddt, J 17.0, 10.0, 7.5, a-H syn), 5.50 (1 
H, ddt, J 17.0, 10.0, 7.5, a-H anti), 4.96 (1 H, dd, J 10.0, 1.2, c-H anti), 4.88 (1 H, dd, 
J 17.0, 1.2, b-H anti), 4.84 (1 H, dd, J 17.0, 1.5, b-H syn), 4.79 (1 H, dd, J 10.0, 1.5, 
c-H syn), 3.97 (3 H, s, MC NMe), 2.68 (3 H, s, NMe anti), 2.61 (1 H, dd, J 14.0, 7.5, 
CHH syn), 2.58 (3 H, s, NMe syn), 2.49 (1 H, dd, J 14.0, 7.5, CHH syn), 2.22 (1 H, 
dd, J 13.7, 7.5, CHH anti), 2.16 (1 H, dd, J 13.7, 7.5, CHH anti), 1.22 (3 H, s, MC 
CMe), 1.18 (3 H, s, CMe syn), 1.17 (3 H, s, CMe anti) and 1.12 (3 H, s, MCQ CMe); 
δC(100 MHz; CDCl3); both diastereoisomers: 159.9, 159.3, 148.3, 147.3, 140.9, 
135.8, 134.1, 133.9, 133.1, 128.5, 128.0, 128.0, 127.5, 125.9, 125.8, 123.4, 122.8, 
122.7, 121.9, 121.7, 121.7, 121.6, 119.8, 119.3, 118.7, 118.5, 118.2, 117.9, 115.5, 
115.5, 107.2, 107.1, 106.9 (2-C), 105.0 (2-C), 55.8 (3-C), 53.7 (3-C), 41.1 (CH2), 39.0 
(CH2), 29.0 (NMe), 28.1 (NMe), 23.3 (3-Me) and 17.6 (3-Me); HRMS-ES (m/z): 




Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), 
propargyl bromide (100 µL of an 80% w/w solution in toluene, 0.933 mmol) and 5-
nitrosalicylaldehyde (125 mg, 0.746 mmol) gave spiropyran 6g (172 mg, 80%) as a 
purple amorphous film, Rf 0.3 (5:95 methanol:ethyl acetate); νmax = 3284, 2927, 1709, 
1608, 1517, 1482, 1334, 1272, 1086, 950, 808 and 747 cm–1; δH(400 MHz; CDCl3; 
48:52 syn:anti) 7.97 - 7.91 (4 H, m, 5'-, 7'-H anti; 5'-, 7'-H syn), 7.23 (1 H, d, J 7.4, 4-
H syn), 7.18 (1 H, d, J 7.5, 4-H anti), 7.14 (2 H, t, J 7.6, 6-H anti; 6-H syn), 6.87 (1 H, 
d, J 10.4, 4'-H syn), 6.85 (1 H, d, J 10.4, 4'-H anti), 6.84 (1 H, t, J 7.6, 5-H anti), 6.83 
(1 H, t, J 7.6, 5-H syn), 6.72 (1 H, d, J 8.5, 8'-H anti), 6.7 (1 H, d, J 8.5, 8'-H syn), 
6.51 (1 H, d, J 7.6, 7-H syn), 6.48 (1 H, d, J 7.6, 7-H anti), 5.82 (1 H, d, J 10.4, 3'-H 
syn), 5.78 (1 H, d, J 10.4, 3'-H anti), 2.68 (3 H, s, NMe anti), 2.66 (1 H, dd, J 16.0, 
2.7, CHH syn), 2.60 (3 H, s, NMe syn), 2.58 (1 H, dd, J 16.0, 2.7, CHH syn), 2.40 (1 
H, dd, J 16.0, 2.7, CHH anti), 2.26 (1 H, dd, J 16.0, 2.7, CHH anti), 1.94 (1 H, t, J 
2.7, C≡CH syn), 1.78 (1 H, t, J 2.7, C≡CH syn), 1.34 (3 H, s, CMe syn) and 1.33 (3 H, 
s, CMe anti); δC(100 MHz; CDCl3); both diastereoisomers: 159.6, 159.2, 148.0, 
147.2, 141.1, 141.1, 134.2, 132.6, 128.9, 128.5, 128.4, 127.9, 126.0, 125.8, 123.5, 
122.8, 122.7, 122.1, 121.3, 121.1, 119.8, 119.6, 118.7, 118.6, 115.6, 115.4, 107.2, 
107.1, 106.0 (2-C), 104.8 (2-C), 80.6 (C≡C), 80.6 (C≡C), 71.4 (C≡C), 70.7 (C≡C), 
54.7 (3-C), 53.0 (3-C), 28.9 (NMe), 28.3 (NMe), 27.4 (CH2), 24.4 (CH2), 23.0 (3-Me) 





Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), 2-
bromoacetophenone (186 mg, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 
0.746 mmol) gave spiropyran 6h (205 mg, 77%) as a purple amorphous film, Rf 0.4 
(5:95 methanol:ethyl acetate); νmax = 2929, 1709, 1682, 1606, 1519, 1486, 1448, 
1338, 1289, 1221, 1089, 955, 912 and 748 cm–1; δH(400 MHz; CDCl3; 15:34:34:17 
MCQ:MC:syn:anti) 8.60 (1 H, br s, MC 5'-H), 8.49 (1 H, d, J 2.7, MCQ 5'-H), 8.36 (1 
H, br d, J 16.0, MC 4'-H), 8.31 (1 H, dd, J 9.2, 2.7, MCQ 7'-H), 7.97 - 7.92 (2 H, m, 
5'-, 7'-H anti), 7.86 (1 H, d, J 2.7, 5'-H syn), 7.83 - 7.74 (4 H, m, MC), 7.70 (1 H, dd, J 
9.0, 2.7, 7'-H syn), 7.61 (2 H, dd, J 8.5, 1.2, a-H syn), 7.60 - 7.50 (4 H, m, MC), 7.43 
(2 H, dd, J 8.4, 2.1, a-H anti), 7.42 - 7.38 (2 H, m, MC), 7.35 - 7.12 (8 H, m, 4-, 6-, b-, 
c-H syn; b-, c-H anti), 7.25 (1 H, br t, J 7.2, MC), 7.06 (1 H, d, J 9.0, 8'-H anti), 7.04 
(1 H, dt, J 7.6, 1.0, 6-H anti), 6.92 (1 H, d, J 10.4, 4'-H anti), 6.91 (1 H, d, J 7.5, 4-H 
anti), 6.85 (1 H, dt, J 7.5, 0.6,  5-H syn), 6.83 (1 H, d, J 10.3, 4'-H syn), 6.62 (1 H, t, J 
7.5, MCQ), 6.56 (1 H, t, J 7.4, 5-H anti), 6.45 (2 H, d, J 7.6, 7-H syn; 7-H anti), 6.41 
(1 H, d, J 9.0, 8'-H syn), 5.96 (1 H, d, J 10.3, 3'-H syn), 5.90 (1 H, d, J 10.4, 3'-H 
anti), 4.60 (1 H, br s, MC CHH), 4.19 (3 H, br s, MC NMe), 4.17 (1 H, br s, MC 
CHH), 3.71 (1 H, d, J 16.6, CHH syn), 3.35 (1 H, d, J 13.8, CHH anti), 3.24 (1 H, d, J 
16.6, CHH syn), 2.77 (1 H, d, J 13.8, CHH anti), 2.72 (3 H, s, NMe anti), 2.58 (3 H, 
s, MCQ NMe), 2.54 (3 H, s, NMe syn), 1.50 (3 H, s, MC CMe), 1.43 (3 H, s, CMe 
anti) and 1.18 (3 H, s, CMe syn); δC(100 MHz; CDCl3); syn diastereoisomer: 198.3 
(C=O), 158.4, 146.4, 141.0, 137.5, 135.4, 132.8, 128.4, 128.3, 128.2, 128.0, 127.7, 
125.1, 122.5, 122.2, 121.8, 119.8, 115.2, 107.4, 107.1 (2-C), 53.8 (3-C), 41.7 (CH2), 
27.9 (NMe) and 23.8 (3-Me); anti diastereoisomer: 198.7 (C=O), 159.8, 148.1, 140.1, 
138.0, 134.6, 132.7, 128.5, 126.1, 126.0, 124.4, 122.8, 121.1, 119.6, 119.0, 118.9, 
118.7, 115.6, 107.1, 103.9 (2-C), 55.6 (3-C), 42.5 (CH2), 29.3 (NMe) and 17.2 (3-
Me); merocyanine / quinoidal merocyanine: 195.4 (C=O), 195.3 (C=O), 183.6 (2-C 
MC), 166.2, 165.3, 147.8, 142.3, 141.6, 134.3, 132.3, 131.6, 129.9, 129.7, 129.6, 
129.5, 129.3, 129.2, 129.1, 128.9, 127.8, 125.9, 125.5, 124.6, 122.3, 120.8, 119.5, 
114.6, 113.9, 61.9 (NMe MC), 53.4 (3-C), 50.9 (3-C), 34.9 (NMe MCQ), 31.8 (CH2), 
26.6 (CH2), 25.9 (3-Me) and 19.9 (3-Me). 12 peaks missing; HRMS-ES (m/z): Found: 
427.1659 (MH+, C26H23O4N2 requires: 427.1658). 
 
1,3,3-Trimethyl-6′-nitrospiro[chromene-2,2'-indoline]23 6i 
Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), 
iodomethane (58 µL, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 0.746 mmol) 
gave spiropyran 6i (60 mg, 30%) as a purple amorphous film, spectroscopically 




Using the same general method, 3-ethyl-1,2-dimethylindole (108 mg, 0.622 mmol), 
benzyl bromide (111 µL, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 0.746 
mmol) gave spiropyran 6m (194 mg, 76%) as a purple amorphous film, Rf 0.4 (5:95 
methanol:ethyl acetate); νmax = 2966, 1707, 1602, 1521, 1495, 1472, 1339, 1289, 
1088, 948 and 749 cm–1; δH(400 MHz; CDCl3; 47:18:35 MC:syn:anti) 8.67 (1 H, br s, 
MC 5'-H), 8.55 (1 H, br d, J 15.9, MC 4'-H), 8.09 - 7.92 (3 H, m, 5'-,7'-H anti; 7'-syn), 
7.85 (1 H, d, J 2.0, 5'-H syn), 7.58 - 7.42 (4 H, m, MC), 7.35 (1 H, br d, J 7.5, MC), 
7.16 - 6.81 (10 H, m, 6-, b-, c-H anti; 6-, a-, b-, c-H syn), 6.68 (1 H, d, J 8.9, 8'-H 
anti), 6.62 (2 H, d, J 6.9, a-H anti), 6.54 (1 H, t, J 7.5, 5-H anti), 6.52 - 6.42 (5 H, m, 
4'-, 7-H anti; 4-, 4'-, 5-H syn), 6.09 (1 H, d, J 10.4, 3'-H anti), 6.00 (1 H, d, J 7.5, 4-H 
anti), 5.54 (1 H, d, J 10.3, 3'-H syn), 3.78 (3 H, br s, MC NMe), 3.55 (1 H, br d, J 
14.5, MC ArCHH), 3.50 (1 H, br d, J 14.5, MC ArCHH), 3.19 (1 H, d, J 14.0, 
ArCHH syn), 3.11 (1 H, d, J 14.0, ArCHH syn), 3.08 (1 H, d, J 13.4, ArCHH anti), 
2.58 (3 H, s, NMe anti), 2.50 (1 H, d, J 13.4, ArCHH anti), 2.42 (3 H, s, NMe syn), 
1.81 - 1.70 (3 H, m, CH2Me anti; CHHMe syn), 1.52 (1 H, dq, J 13.8, 7.3, CHHMe 
syn), 0.88 (3 H, t, J 7.4, CMe anti), 0.85 (3 H, t, J 7.3, CMe syn) and 0.42 (3 H, t, J 
6.9,  MC CMe); δC(100 MHz; CDCl3); anti diastereoisomer: 159.4, 147.4, 142.9, 
136.7, 133.2, 131.4, 129.1, 128.2, 127.4, 126.4, 125.9, 124.9, 123.6, 122.9, 122.2, 
118.6, 115.5, 107.1, 105.7 (2-C), 58.6 (3-C), 37.0 (ArCH2), 29.3 (NMe), 28.1 
(CH2CH3) and 8.9 (CH2CH3); syn diastereoisomer: 159.1, 150.9, 140.9, 138.9, 137.5, 
132.7, 128.0, 127.8, 127.5, 126.7, 126.3, 125.7, 122.6, 121.0, 120.6, 118.4, 115.6, 
107.3, 104.7 (2-C), 53.8 (3-C), 35.5 (ArCH2), 31.8 (NMe), 27.9 (CH2CH3) and 8.6 
(CH2CH3); merocyanine: 180.6 (2-C), 169.9, 150.9, 141.3, 131.5, 130.5, 130.0, 129.8, 
129.4, 129.2, 128.8, 128.8, 128.7, 128.1, 120.2, 119.4, 119.2, 114.1, 113.1, 64.1 
(NMe), 47.2 (3-C), 33.5 (ArCH2), 22.7 (CH2CH3) and 8.8 (CH2CH3); HRMS-ES 




Using the same general method, 3-ethyl-1,2-dimethylindole (108 mg, 0.622 mmol), 2-
bromobenzyl bromide (233 mg, 0.933 mmol) and 5-nitrosalicylaldehyde (125 mg, 
0.746 mmol) gave spiropyran 6n (191 mg, 66%) as a purple amorphous film, Rf 0.5 
(5:95 methanol:ethyl acetate); νmax = 2967, 1708, 1602, 1519, 1470, 1337, 1288, 
1088, 948 and 749 cm–1; δH(400 MHz; CDCl3; 65:6:29 MC:syn:anti) 8.49 (1 H, br s, 
MC 5'-H), 8.21 (1 H, br d, J 15.6, MC 4'-H), 8.01 - 7.85 (2 H, m, 5'-, 7'-H anti), 7.60 - 
7.40 (4 H, m, MC), 7.35 (1 H, br t, J 6.9, MC), 7.29 (1 H, d, J 7.9, a-H anti), 7.10 (1 
H, t, J 7.5, 6-H anti), 7.01 (2 H, br d, J 6.9, MC), 7.00 - 6.92 (3 H, m, b-, c-, d-H anti), 
6.90 (1 H, d, J 10.4, 4'-H anti), 6.71 (1 H, d, J 8.9, 8'-H anti), 6.55 (1 H, t, J 7.5, 5-H 
anti), 6.44 (1 H, d, J 7.5, 7-H anti), 6.08 (1 H, d, J 10.4, 3'-H anti), 5.91 (1 H, d, J 7.5, 
4-H anti), 5.75 (1 H, d, J 10.3, 3'-H syn), 4.13 (3 H, br s, MC NCH3), 3.62 (1 H, br d, 
J 13.7, MC ArCHH), 3.52 (1 H, br d, J 13.7, MC ArCHH), 3.05 (2 H, br s, ArCHH 
anti), 2.73 - 2.38 (2 H, m, MC CHHMe), 2.60 (3 H, s, NMe anti), 2.56 (3 H, s, NMe 
syn), 1.91 (1 H, dq, J 14.8, 7.4, CHHMe anti), 1.85 (1 H, dq, J 14.8, 7.4, CHHMe 
anti), 1.80 - 1.72 (2 H, m, CHHMe syn), 0.89 (3 H, t, J 7.4, CMe anti), 0.62 (3 H, t, J 
7.3, CMe syn) and 0.36 (3 H, br s, MC CMe); δC(100 MHz; CDCl3); anti 
diastereoisomer: 159.4, 148.3, 140.9, 136.6, 132.5, 132.4, 129.7, 128.2, 128.0, 127.5, 
126.4, 126.3, 123.9, 122.9, 121.9, 119.2, 118.4, 115.5, 107.2, 105.5 (2-C), 58.4 (3-C), 
35.3 (ArCH2), 29.3 (NMe), 28.2 (CH2CH3) and 8.9 (CH2CH3); syn diastereoisomer: 
158.8, 147.8, 141.2, 137.7, 132.9, 131.6, 127.2, 127.0, 126.7, 126.6, 125.7, 124.8, 
123.7, 122.6, 121.2, 115.9, 106.8, 104.5 (2-C), 53.8 (3-C), 34.8 (ArCH2), 31.8 (NMe), 
28.2 (CH2CH3) and 8.6 (CH2CH3)(3 peaks missing); merocyanine: 180.9 (2-C), 168.1, 
150.2, 142.7, 139.3, 138.4, 133.2, 132.1, 132.0, 131.6, 130.0, 129.6, 129.3, 127.8, 
126.0, 124.2, 120.9, 119.4, 119.3, 114.4, 113.6, 63.0 (NMe), 44.6 (3-C), 32.8 
(ArCH2), 22.9 (CH2CH3) and 8.6 (CH2CH3); HRMS-ES (m/z): Found: 491.0968 




Using the same general method, 1-benzyl-2,3-dimethylindole (136 mg, 0.578 mmol), 
benzyl bromide (103 µL, 0.867 mmol) and 5-nitrosalicylaldehyde (116 mg, 0.694 
mmol) gave spiropyran 6o (203 mg, 74%) as a purple amorphous film, Rf 0.6 (5:95 
methanol:ethyl acetate); νmax = 3028, 2926, 1710, 1605, 1517, 1479, 1334, 1271, 
1088, 948, 807 and 747 cm–1; δH(400 MHz; CDCl3; 22:78 syn:anti) 8.01 (1 H, dd, J 
9.0, 2.4, 7'-H syn), 7.95 - 7.90 (2 H, m, 5'-, 7'-H anti), 7.86 (1 H, d, J 2.4, 5'-H syn), 
7.25 - 7.06 (12 H, m, a'-, b'-, c'-, b-H anti; b'-, c'-, b-H syn), 7.05 - 6.94 (5 H, m, 6-H 
anti; a-, 4-, 6-H syn), 6.86 (1 H, d, J 10.4, 4'-H anti), 6.80 (1 H, d, J 9.0, 8'-H syn), 
6.78 (1 H, t, J 7.5, 5-H syn), 6.70 (1 H, d, J 8.6, 8'-H anti), 6.68 - 6.60 (3 H, m, 5-, a-
H anti), 6.53 (1 H, d, J 10.3, 4'-H syn), 6.30 (1 H, d, J 7.8, 7-H anti), 6.29 (1 H, d, J 
7.1, 4-H anti), 6.24 (1 H, d, J 7.8, 7-H syn), 6.01 (1 H, d, J 10.4, 3'-H anti), 5.68 (1 H, 
d, J 10.3, 3'-H syn), 4.48 (1 H, d, J 16.5, NCHH anti), 4.22 (1 H, d, J 16.2, NCHH 
syn), 4.17 (1 H, d, J 16.5,NCHH anti), 3.99 (1 H, d, J 16.2, NCHH syn), 3.18 (1 H, d, 
J 13.5, 3-CHH syn), 3.16 (1 H, d, J 13.5, 3-CHH syn), 2.81 (1 H, d, J 12.6, 3-CHH 
anti), 2.79 (1 H, d, J 12.6, 3-CHH anti), 1.34 (3 H, s, Me syn) and 1.20 (3 H, s, Me 
anti); δC(100 MHz; CDCl3); anti diastereoisomer: 159.8, 147.9, 141.1, 138.6, 136.7, 
131.4, 131.0, 128.9, 128.7, 128.0, 127.4, 127.1, 126.5, 126.4, 126.3, 126.1, 124.7, 
122.8, 121.9, 119.0, 115.7, 108.0, 107.9 (2-C), 57.8 (3-C), 48.1 (NCH2), 42.4 (3-CH2) 
and 17.3 (3-Me); syn diastereoisomer: 158.9, 146.4, 141.2, 138.4, 137.4, 135.6, 132.2, 
128.8, 128.5, 128.3, 127.6, 127.4, 126.6, 125.8, 122.7, 122.4, 121.1, 119.9, 119.0, 
118.7, 115.9, 108.2, 105.0 (2-C), 54.9 (3-C), 46.9 (NCH2), 39.4 (3-CH2) and 24.2 (3-




Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), benzyl 
bromide (111 µL, 0.933 mmol) and 5-bromosalicylaldehyde (150 mg, 0.746 mmol) 
gave spiropyran 6p (222 mg, 83%) as a purple amorphous film, Rf 0.4 (5:95 
methanol:ethyl acetate); νmax = 3027, 2926, 1711, 1605, 1474, 1361, 957, 815, 752 
and 703 cm–1; δH(400 MHz; CDCl3; 5:26:69 MC:syn:anti) 8.31 (1 H, br d, J 15.9, 
MC 4'-H), 7.70 - 7.54 (3 H, m, MC), 7.48 - 7.40 (4 H, m, MC), 7.18 (1 H, dd, J 8.5, 
2.4, 7'-H syn), 7.15 - 7.01 (9 H, m, 5'-, 7-', 6-, c-H anti; 5'-, 6-, b-, c-H syn), 6.98 - 
6.94 (3 H, m, 4-, a-H syn), 6.79 (1 H, d, J 10.3, 4'-H anti), 6.77 (1 H, t, J 7.4, 5-H 
syn), 6.68 (1 H, d, J 8.5, 8'-H syn), 6.62 (2 H, dd, J 7.8, 1.6, a-H anti), 6.56 (1 H, t, J 
7.2, 5-H anti), 6.53 - 6.50 (2 H, m, 7-, 8'-H anti), 6.48 (1 H, d, J 10.2, 4'-H syn), 6.42 
(1 H, d, J 7.8, 7-H syn), 6.08 (1 H, d, J 7.2, 4-H anti), 5.82 (1 H, d, J 10.3, 3'-H anti), 
5.43 (1 H, d, J 10.2, 3'-H syn), 3.72 (3 H, br s, MC NMe), 3.42 (2 H, s, MC CH2), 
3.20 (1 H, d, J 13.5, CHH syn), 3.05 (1 H, d, J 13.5, CHH syn), 2.72 (3 H, s, NMe 
anti), 2.71 (1 H, d, J 12.2, CHH anti), 2.60 (1 H, d, J 12.2, CHH anti), 2.51 (3 H, s, 
NMe syn), 1.18 (3 H, s, MC CMe), 1.16 (3 H, s, CMe syn) and 1.13 (3 H, s, CMe 
anti); δC(100 MHz; CDCl3); anti diastereoisomer: 153.7, 148.6, 137.2, 132.4, 131.6, 
131.1, 129.1, 129.0, 127.8, 127.5, 127.2, 126.3, 124.9, 120.9, 118.2, 117.0, 111.9, 
106.9, 105.9 (2-C), 57.0 (3-C), 41.4 (CH2), 29.3 (NMe) and 16.7 (3-Me); syn 
diastereoisomer: 152.9, 147.3, 137.8, 135.9, 132.3, 129.1, 128.8, 127.9, 127.1, 126.2, 
122.3, 121.2, 120.7, 120.0, 119.2, 117.1, 112.2, 107.1, 102.8 (2-C), 53.9 (3-C), 39.3 
(CH2), 28.2 (NMe) and 23.4 (3-Me); HRMS-ES (m/z): Found: 432.0954 (MH+, 
C25H23ONBr requires: 432.0963). 
 
Methyl anti-(2R*,3S*)- and syn-(2R*,3R*)-3-benzyl-1,3-dimethylspiro[chromene-
2,2'-indoline]-6′-carboxylate 6q 
Using the same general method, 1,2,3-trimethylindole (99 mg, 0.622 mmol), benzyl 
bromide (111 µL, 0.933 mmol) and methyl 3-formyl-4-hydroxybenzoate (134 mg, 
0.746 mmol) gave spiropyran 6q (179 mg, 70%) as a purple amorphous film, Rf 0.3 
(5:95 methanol:ethyl acetate); νmax = 2950, 1711, 1647, 1606, 1483, 1449, 1360, 
1286, 1266, 1206, 1171, 953, 767 and 753 cm–1; δH(400 MHz; CDCl3; 21:21:58 
MC:syn:anti) 8.42 (1 H, d, J 16.2, MC 4'-H), 8.12 (1 H, d, J 1.9, MC 5'-H), 7.81 (1 H, 
dd, J 8.5, 2.1, 7'-H syn), 7.75 - 7.71 (2 H, m, 5'-H syn and anti), 7.70 (1 H, dd, J 8.0, 
2.1, 7'-H anti), 7.66 (1 H, d, J 16.2, MC 3'-H), 7.50 - 7.43 (3 H, m, MC), 7.30 (1 H, d, 
J 8.0, MC), 7.18 - 6.92 (10 H, m, J 7.9, 6-, b-, c-H anti; 6-, a-, b-, c-H syn), 6.90 (1 H, 
d, J 10.3, 4'-H anti), 6.82 (1 H, d, J 8.2, 8'-H syn), 6.79 (1 H, t, J 7.5, 5-H syn), 6.65 (1 
H, d, J 8.0, 8'-H anti), 6.62 (2 H, dd, J 8.0, 1.5,  a-H anti), 6.58 (1 H, t, J 7.2, 5-H 
anti), 6.57 (1 H, d, J 10.2, 4'-H syn), 6.53 (1 H, d, J 7.8, 7-H anti), 6.46 (1 H, d, J 7.5, 
4-H syn), 6.45 (1 H, d, J 7.5, 7-H syn), 6.04 (1 H, d, J 7.2, 4-H anti), 5.84 (1 H, d, J 
10.3, 3'-H anti), 5.47 (1 H, d, J 10.2, 3'-H syn), 3.82 (3 H, s, OMe syn), 3.81 (3 H, s, 
OMe anti), 3.80 (3 H, s, MC OMe), 3.76 (3 H, s, MC NMe), 3.47 (2 H, s, MC CH2), 
3.20 (1 H, d, J 13.5, CHH syn), 3.07 (1 H, d, J 13.5, CHH syn), 2.71 (3 H, s, NMe 
anti), 2.70 (1 H, d, J 12.2, CHH anti), 2.63 (1 H, d, J 12.2, CHH anti), 2.52 (3 H, s, 
NMe syn), 1.19 (3 H, s, CMe syn), 1.19 (3 H, s, MC CMe) and 1.12 (3 H, s, CMe 
anti); δC(100 MHz; CDCl3); anti diastereoisomer: 166.8 (C=O), 158.6, 148.5, 137.1, 
132.4, 131.8, 131.6, 131.0, 129.6, 128.8, 127.9, 127.2, 127.1, 126.3, 125.0, 120.2, 
118.3, 115.1, 107.1, 106.6 (2-C), 57.0 (3-C), 51.9 (OMe), 41.5 (CH2), 29.3 (NMe) and 
16.6 (3-Me); syn diastereoisomer: 166.8 (C=O), 157.8, 147.2, 140.7, 137.7, 135.9, 
129.0, 128.7, 128.2, 128.0, 127.8, 126.2, 122.3, 122.1, 119.4, 118.5, 115.2, 114.2, 
107.1, 103.6 (2-C), 58.1 (3-C), 52.2 (OMe), 39.3 (CH2), 28.1 (NMe) and 23.6 (3-Me); 
merocyanine: 181.4 (2-C), 166.1 (C=O), 164.5, 151.7, 142.2, 136.5, 133.5, 133.1, 
129.8, 129.4, 128.9, 128.5, 123.6, 122.3, 121.9, 120.4, 119.0, 118.5, 112.9, 54.1 
(NMe), 52.0 (OMe), 47.7 (3-C), 34.5 (CH2) and 25.2 (3-Me); HRMS-ES (m/z): 
Found: 412.1910 (MH+, C27H26O3N requires: 412.1912). 
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